FOCUS ISSUE: PROVE IT-TIMI 22
Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy
A PROVE IT-TIMI 22 Substudy
Stephen D. Wiviott, MD*, ,*,
Christopher P. Cannon, MD, FACC*,,
David A. Morrow, MD, MPH, FACC*,,
Kausik K. Ray, MD,
Marc A. Pfeffer, MD, PhD, FACC*,
Eugene Braunwald, MD, MACC*, for the PROVE IT-TIMI 22 Investigators
* Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
The TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
Manuscript received January 27, 2005;
revised manuscript received March 28, 2005,
accepted April 4, 2005.
* Reprint requests and correspondence: Dr. Stephen D. Wiviott, TIMI Study Group, 350 Longwood Avenue, 1st Floor, Boston, Massachusetts 02115 (Email: swiviott{at}partners.org).
OBJECTIVES: This study sought to evaluate the safety and efficacy of achieving very low calculated low-density lipoprotein (LDL) levels with intensive statin therapy.
BACKGROUND: Intensive statin therapy reduces clinical events occurring after acute coronary syndrome (ACS) and may result in LDL levels markedly lower than guideline levels. Prior epidemiologic and preclinical studies raise concerns about the safety of very low cholesterol levels.
METHODS: The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) study compared intensive therapy (atorvastatin, 80 mg) and moderate therapy (pravastatin, 40 mg) in patients after ACS. Patients treated with atorvastatin were divided by four-month LDL values into groups: >100, >80 to 100 (reference-range-meeting guidelines), >60 to 80, >40 to 60, and <40 mg/dl. Baseline, clinical, and safety data were compared among groups achieving guideline recommendation levels or lower.
RESULTS: Among 1,825 patients with four-month LDL, 91% were at goal (<100 mg/dl). The distribution was >80 to 100 mg/dl (14%), >60 to 80 mg/dl (31%), >40 to 60 mg/dl (34%), and <40 mg/dl (11%). Those with lower LDL levels were more often male, older, and diabetic, and had lower baseline LDL levels. They had prior statin therapy and fewer prior myocardial infarctions (MI). There were no significant differences in safety parameters, including muscle, liver, or retinal abnormalities, intracranial hemorrhage, or death, in the very low LDL groups. The <40 mg/dl and 40 to 60 mg/dl groups had fewer major cardiac events (death, MI, stroke, recurrent ischemia, revascularization).
CONCLUSIONS: Compared with patients treated with an accepted LDL goal (80 to 100 mg/dl), there was no adverse effect on safety with lower achieved LDL levels, and apparent improved clinical efficacy. These data identify no intrinsic safety concern of achieving low LDL and, therefore, a strategy of intensive treatment need not be altered in patients achieving very low LDL levels.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | LDL = low-density lipoprotein | | MI = myocardial infarction | | PROVE IT-TIMI 22 = Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 | | ULN = upper limit of normal |
|
This article has been cited by other articles:
|
|
|
|
 
L. B. Goldstein
The Complex Relationship Between Cholesterol and Brain Hemorrhage
Circulation,
April 28, 2009;
119(16):
2131 - 2133.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. F. Whayne Jr
Response to Letter of Mascitelli L, Ravnskov U, Pezzetta F, and Goldstein M
Angiology,
February 1, 2009;
60(1):
129 - 130.
[PDF]
|
|
|
|
|
|
|
R. R. Giraldez, R. P. Giugliano, S. Mohanavelu, S. A. Murphy, C. H. McCabe, C. P. Cannon, and E. Braunwald
Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis
J. Am. Coll. Cardiol.,
September 9, 2008;
52(11):
914 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. B Newman, M. Szarek, H. M Colhoun, D J. Betteridge, P. N Durrington, G. A Hitman, H A. W Neil, D. A Demicco, S. Auster, and J. H Fuller
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)
Diabetes and Vascular Disease Research,
September 1, 2008;
5(3):
177 - 183.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Steinberg, C. K. Glass, and J. L. Witztum
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Circulation,
August 5, 2008;
118(6):
672 - 677.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. O'Keefe, K. A. Bybee, and C. J. Lavie
Intensive Lipid Intervention in the Post-ENHANCE Era
Mayo Clin. Proc.,
August 1, 2008;
83(8):
867 - 869.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rodriguez-Yanez, J. Agulla, R. Rodriguez-Gonzalez, T. Sobrino, and J. Castillo
Review: Statins and stroke
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
157 - 166.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. W. Nesto
LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?
Clin. Diabetes,
January 1, 2008;
26(1):
8 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tabas, K. J. Williams, and J. Boren
Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications
Circulation,
October 16, 2007;
116(16):
1832 - 1844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Leeper, R. Ardehali, E. M. deGoma, and P. A. Heidenreich
Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival
Circulation,
August 7, 2007;
116(6):
613 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Afilalo, A. A Majdan, and M. J Eisenberg
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Heart,
August 1, 2007;
93(8):
914 - 921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qian, R. J. Schmidt, Y. Zhang, S. Chu, A. Lin, H. Wang, X. Wang, T. P. Beyer, W. R. Bensch, W. Li, et al.
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
J. Lipid Res.,
July 1, 2007;
48(7):
1488 - 1498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Davidson and J. G. Robinson
Safety of Aggressive Lipid Management
J. Am. Coll. Cardiol.,
May 1, 2007;
49(17):
1753 - 1762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Lavie, R. V. Milani, and J. H. O'Keefe
Statin Wars-Emphasis on Potency vs Event Reduction and Safety?
Mayo Clin. Proc.,
May 1, 2007;
82(5):
539 - 542.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. N. Patel, M. H. Shishehbor, and D. L. Bhatt
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Eur. Heart J.,
March 2, 2007;
28(6):
664 - 672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Deedwania, P. H. Stone, C. N. Bairey Merz, J. Cosin-Aguilar, N. Koylan, D. Luo, P. Ouyang, R. Piotrowicz, K. Schenck-Gustafsson, P. Sellier, et al.
Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE)
Circulation,
February 13, 2007;
115(6):
700 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S Houslay, J. Sarma, and N. G Uren
The effect of intensive lipid lowering on coronary atheroma and clinical outcome
Heart,
February 1, 2007;
93(2):
149 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Drexel
Reducing risk by raising HDL-cholesterol: the evidence
Eur. Heart J. Suppl.,
October 1, 2006;
8(suppl_F):
F23 - F29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hulten, J. L. Jackson, K. Douglas, S. George, and T. C. Villines
The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.
Arch Intern Med,
September 25, 2006;
166(17):
1814 - 1821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Keller and L. Lemberg
Secondary prevention of coronary artery disease in elderly persons: a treatise on a report by the american heart association.
Am. J. Crit. Care.,
September 1, 2006;
15(5):
514 - 518.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Jacobson
The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?
Mayo Clin. Proc.,
September 1, 2006;
81(9):
1225 - 1231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Stroke Prevention by Aggressive Reduction in C
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
N. Engl. J. Med.,
August 10, 2006;
355(6):
549 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
July 18, 2006;
48(2):
386 - 395.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas
Highlights of the Year in JACC 2005
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
184 - 202.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Statins in ACS Patients: Intensity of Treatment, Timing of Benefit
Journal Watch Cardiology,
December 9, 2005;
2005(1209):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
Can LDL Levels Be Too Low?
Journal Watch Gastroenterology,
November 29, 2005;
2005(1129):
4 - 4.
[Full Text]
|
|
|
|
|
|
|
Can LDL Levels Be Too Low?
Journal Watch (General),
November 25, 2005;
2005(1125):
1 - 1.
[Full Text]
|
|
|
|
|
|
|
C. P. Cannon
The IDEAL Cholesterol: Lower Is Better
JAMA,
November 16, 2005;
294(19):
2492 - 2494.
[Full Text]
[PDF]
|
|
|
|
